Amphion Innovations plc

Partner Company, Motif BioSciences Ltd., to be re-named Motif Bio plc on re-registration as public listed company

Update re: Intention to Float on AIM

Expected Admission date set for clinical stage biopharmaceutical company developing new antibiotics

London and New York, 20 March 2015 - Pursuant to the Company’s statement on 2 February 2015, Amphion is pleased to confirm that its Partner Company, Motif Bio plc, will seek admission of its ordinary shares to trading on the AIM market of the London Stock Exchange.  Admission is expected on 31 March 2015.  As of 31 December 2014, Amphion owned approximately 38% of Motif. 

Motif is a clinical stage biopharmaceutical company, which specialises in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Upon admission, Motif will have a lead antibiotic candidate, iclaprim, in clinical development and MTF-001, a preclinical stage programme to design a best-in-class dihydrofolatereductase inhibitor (DHFRi). Discussions and negotiations with academic institutions and pharmaceutical companies are under way to build a portfolio of antibiotic candidates through licensing.

The Directors of Motif anticipate that iclaprim could be ready for commercialisation within approximately 36 months.

For further information please contact

Amphion Innovations
Charlie Morgan
+1 212 210 6224

Yellow Jersey PR
Dominic Barretto / Fiona Walker
+44 7768 537 739

Panmure Gordon Limited
Freddy Crossley / Fred Walsh (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 020 7886 2500

About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses.

We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.

On the web: